Unit PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands; Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Unit PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands; Faculty of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
J Clin Epidemiol. 2019 Apr;108:44-53. doi: 10.1016/j.jclinepi.2018.12.003. Epub 2018 Dec 8.
We reviewed measures used to estimate adherence and persistence to multiple cardiometabolic medications from prescription data, particularly for blood pressure-lowering, lipid-lowering, and/or glucose-lowering medication, and give guidance on which measures to choose.
A literature search of Medline, Embase, and PsycINFO databases was conducted to identify studies assessing medication adherence and/or persistence for patients using multiple cardiometabolic medications. Two reviewers performed the study selection process independently.
From the 54 studies assessing adherence, only 36 (67%) clearly described the measures used. Five measures for adherence were identified, including adherence to "all," to "any," to "both" medication, "average adherence," and "highest/lowest adherence". From the 22 studies assessing persistence, only six (27%) clearly described the measures used. Three measures for persistence were identified, including persistence with "all," with "both," and with "any" medication. Less than half of the studies explicitly considered medication switches when relevant.
From the identified measures, the "any medication" measure is most suitable for identifying patients in need of an intervention, whereas the "all medication" measure is useful for assessing the effect of interventions. More attention is needed for adequate measurement definitions when reporting on and interpreting adherence or persistence estimates to multiple medications.
我们回顾了从处方数据估算多种心血管代谢药物的依从性和持久性的方法,特别是针对降压、降脂和/或降糖药物,并就应选择哪些方法提供了指导。
对 Medline、Embase 和 PsycINFO 数据库进行了文献检索,以确定评估使用多种心血管代谢药物的患者药物依从性和/或持久性的研究。两名评审员独立进行了研究选择过程。
在评估依从性的 54 项研究中,只有 36 项(67%)明确描述了所使用的方法。确定了 5 种依从性测量方法,包括对“所有”、“任何”、“两者”药物的依从性、“平均依从性”和“最高/最低依从性”。在评估持久性的 22 项研究中,只有 6 项(27%)明确描述了所使用的方法。确定了 3 种持久性测量方法,包括对“所有”、“两者”和“任何”药物的持久性。当相关时,不到一半的研究明确考虑了药物转换。
在所确定的方法中,“任何药物”测量方法最适合识别需要干预的患者,而“所有药物”测量方法对于评估干预效果有用。在报告和解释对多种药物的依从性或持久性估计时,需要更加注意充分定义测量方法。